Skip to main content
. 2011 May;25(5):1653–1663. doi: 10.1096/fj.10-176917

Figure 2.

Figure 2.

Inhibition of myostatin increases body weight and reduces muscle atrophy in CKD mice. A, B) Inhibitory activity of the anti-myostatin peptibody against either myostatin (A) or activin A (B) was measured using a cell-based reporter assay (n=3) as described previously (27). C) CKD mice treated with the peptibody or PBS (n=25/group) had body weights measured repeatedly over 28 d; peptibody-treated CKD mice gained more weight. *P < 0.05. D) Cryosections of TA muscles were immunostained with anti-laminin and DAPI to assess myofiber sizes. Scale bars = 50 μm. E) Distribution of myofiber sizes was shifted to the right (larger size) in peptibody-treated CKD mice (n=3 mice/group; 600 myofibers/muscle measured). RLU, relative light units; Ctrl, control; CSA, cross-sectional area.